GlassScriptPhysician profile
Hamza Idrees Khan
NPI 1265012967
$1,639.03
in general payments reported to CMS, 2019-2025
15 companies · $1,031 in 2025
The $1,031 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $109 · 2024: $498 · 2025: $1,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,639.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $420.04 | 2024-2025 | |
| Janssen Biotech, INC. | $298.73 | 2024-2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $201.32 | 2024-2025 | Entyvio, Gattex, Eohilia |
| Janssen Scientific Affairs, LLC | $136.32 | 2024 | Stelara, Remicade, Tremfya |
| E.R. Squibb & Sons, L.L.C. | $109.09 | 2023 | Zeposia |
| Genzyme Corporation | $97.28 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $66.55 | 2025 | Dupixent |
| Celltrion USA INC. | $53.15 | 2024-2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $46.03 | 2024-2025 | Iqirvo |
| Ardelyx, INC. | $44.80 | 2024 | Ibsrela |
| Madrigal Pharmaceuticals | $43.24 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $36.88 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.37 | 2024 | Xifaxan |
| Aimmune Therapeutics, INC. | $25.69 | 2025 | Zenpep |
| Evoke Pharma, INC. | $23.54 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamza Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.